IPAB has dismissed the review petition filed by Roche & OSI Pharmaceuticals against an earlier IPAB order for receiving additional documents from Mylan Laboratories in a patent battle between the pharma companies, relating to Erlotinib hydrochloride, an active ingredient for anti-cancer drug Tarceva.